

Short-Course Radiation plus Temozolomide in Elderly Patients

New England Journal of Medicine

376, 1027-1037

DOI: [10.1056/nejmoa1611977](https://doi.org/10.1056/nejmoa1611977)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Glioblastoma Multiforme (GBM) in the Elderly: Initial Treatment Strategy and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2016, 96, E87-E88.	0.4	1
2	New chemoradiation standard for elderly patients with glioblastoma. Nature Reviews Clinical Oncology, 2017, 14, 330-330.	12.5	0
3	Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals. Journal of the Neurological Sciences, 2017, 378, 3-8.	0.3	13
5	Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature. World Neurosurgery, 2017, 105, 53-62.	0.7	16
6	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	5.1	816
7	Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience. Radiation Oncology, 2017, 12, 77.	1.2	4
8	When less is better: care of the elderly with glioblastoma. Neuro-Oncology, 2017, 19, 879-879.	0.6	0
9	Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival. Journal of Neuro-Oncology, 2017, 134, 107-118.	1.4	25
10	Radiation plus Temozolomide in Patients with Glioblastoma. New England Journal of Medicine, 2017, 376, 2195-2197.	13.9	22
11	Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma. Current Treatment Options in Oncology, 2017, 18, 66.	1.3	12
12	Treatment of Glioblastoma in Older Adults. Current Oncology Reports, 2017, 19, 81.	1.8	45
13	Improving diagnosis and management of primary brain tumors. Current Opinion in Neurology, 2017, 30, 639-642.	1.8	5
14	Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. Journal of Neuro-Oncology, 2017, 135, 529-534.	1.4	20
15	Randomized Trial for Short-Term Radiation Therapy With Temozolomide in Elderly Patients With Glioblastoma. Neurosurgery, 2017, 81, N21-N23.	0.6	4
16	New Hypofractionation Radiation Strategies for Glioblastoma. Current Oncology Reports, 2017, 19, 58.	1.8	10
17	The Changing Paradigm of Radiotherapy in the Elderly Population. Cancer Journal (Sudbury, Mass), 2017, 23, 223-230.	1.0	10
18	Management of glioblastoma in elderly patients. Journal of the Neurological Sciences, 2017, 380, 250-255.	0.3	40
19	Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes. Clinical Oncology, 2017, 29, 739-747.	0.6	29

#	ARTICLE	IF	CITATIONS
20	Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard. <i>Future Science OA</i> , 2017, 3, FSO210.	0.9	1
21	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	1.4	21
22	Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. <i>Journal of Neuro-Oncology</i> , 2017, 134, 377-385.	1.4	16
23	Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model?. <i>Journal of Neuro-Oncology</i> , 2017, 134, 423-431.	1.4	11
27	Radiation therapy for older patients with brain tumors. <i>Radiation Oncology</i> , 2017, 12, 101.	1.2	32
28	Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. <i>Neurochirurgie</i> , 2017, 63, 433-443.	0.6	16
29	Glioblastoma Treatment in the Elderly. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 667-676.	1.0	32
30	<i>BICD1</i> expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas. <i>Oncotarget</i> , 2017, 8, 113766-113791.	0.8	9
31	Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. <i>F1000Research</i> , 2017, 6, 1892.	0.8	72
32	The Changing Paradigm of Radiotherapy in the Elderly Population. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 223-230.	1.0	2
33	Management of Elderly Patients with Glioblastoma after CE.6. <i>Frontiers in Oncology</i> , 2017, 7, 196.	1.3	2
36	Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report. <i>Radiation Oncology</i> , 2017, 12, 197.	1.2	25
38	Treatment of Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 629-638.	2.5	94
39	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	0.8	561
41	ARTE and craft of bevacizumab in elderly patients with glioblastoma. <i>Annals of Oncology</i> , 2018, 29, 1346-1347.	0.6	0
42	Recent advances in precision oncology research. <i>Npj Precision Oncology</i> , 2018, 2, 11.	2.3	39
43	Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. <i>Oncology</i> , 2018, 95, 39-42.	0.9	5
44	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	0.6	65

#	ARTICLE	IF	CITATIONS
45	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
46	Brain Tumors. <i>American Journal of Medicine</i> , 2018, 131, 874-882.	0.6	121
47	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018, 31, 168-179.	1.3	2
48	Chemotherapy of High-Grade Astrocytomas in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 116-144.	1.3	5
49	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1433982.	2.1	38
50	SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. <i>Neuro-Oncology</i> , 2018, 20, 621-631.	0.6	33
51	Autophagy mediates glucose starvation-induced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival. <i>Cell Death and Disease</i> , 2018, 9, 213.	2.7	48
52	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
53	Management of elderly patients with glioblastoma-multiforme—a systematic review. <i>British Journal of Radiology</i> , 2018, 91, 20170271.	1.0	9
54	Where does O ⁶ -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?. <i>Cancer</i> , 2018, 124, 1316-1318.	2.0	9
55	Surgical treatment of glioblastoma in the elderly: the impact of complications. <i>Journal of Neuro-Oncology</i> , 2018, 138, 123-132.	1.4	48
56	Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 155-162.	1.4	4
57	Tumor treating fields: a new approach to glioblastoma therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 447-453.	1.4	38
59	Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program-Based Study. <i>World Neurosurgery</i> , 2018, 111, e323-e334.	0.7	15
60	Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 108-113.	0.3	15
61	Management and Outcomes in the Oldest-Old Population with Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 199-205.	0.3	10
62	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	0.6	92
63	Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas. <i>Cancer</i> , 2018, 124, 2674-2676.	2.0	11

#	ARTICLE	IF	CITATIONS
64	Targeting Long Noncoding RNA HMMR-AS1 Suppresses and Radiosensitizes Glioblastoma. <i>Neoplasia</i> , 2018, 20, 456-466.	2.3	37
65	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061.	0.5	33
66	Survival in elderly glioblastoma patients treated with bevacizumab-based regimens in the United States. <i>Neuro-Oncology Practice</i> , 2018, 5, 251-261.	1.0	10
67	Disrupting CD47-SIRP α axis alone or combined with autophagy depletion for the therapy of glioblastoma. <i>Carcinogenesis</i> , 2018, 39, 689-699.	1.3	58
68	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. <i>Neuro-Oncology</i> , 2018, 20, 174-183.	0.6	33
69	Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. <i>Journal of Neuro-Oncology</i> , 2018, 136, 307-315.	1.4	21
70	Survival improvements with adjuvant therapy in patients with glioblastoma. <i>ANZ Journal of Surgery</i> , 2018, 88, 196-201.	0.3	18
71	Do carer's levels of unmet needs change over time when caring for patients diagnosed with high-grade glioma and how are these needs correlated with distress?. <i>Supportive Care in Cancer</i> , 2018, 26, 275-286.	1.0	44
72	Glioma epigenetics: From subclassification to novel treatment options. <i>Seminars in Cancer Biology</i> , 2018, 51, 50-58.	4.3	377
73	Contemporary management of high-grade gliomas. <i>CNS Oncology</i> , 2018, 7, 51-65.	1.2	32
74	SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 22-28.	1.2	56
75	Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. <i>Journal of Neuro-Oncology</i> , 2018, 136, 403-411.	1.4	29
76	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. , 2018, 184, 13-41.		230
77	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. <i>Anti-Cancer Drugs</i> , 2018, 29, 924-928.	0.7	2
78	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	0.8	39
79	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	0.8	108
80	Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis. <i>ASN Neuro</i> , 2018, 10, 175909141881826.	1.5	80
81	Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?. <i>Radiology and Oncology</i> , 2018, 52, 121-128.	0.6	42

#	ARTICLE	IF	CITATIONS
83	Short Course versus Standard Course of Radiotherapy in Glioblastoma Multiforme. Journal of Nuclear Medicine & Radiation Therapy, 2018, 09, .	0.2	1
84	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	0.6	78
85	Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma. Seminars in Oncology Nursing, 2018, 34, 443-453.	0.7	13
86	The 2016 World Health Organization classification of tumours of the central nervous system. Presse Medicale, 2018, 47, e187-e200.	0.8	75
87	Effect of radiotherapy and chemotherapy on levels of serum S100B, IL-6, and IL-17 in patients with malignant glioma. European Journal of Inflammation, 2018, 16, 205873921880432.	0.2	2
88	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). Biomedical Reports, 2018, 10, 3-9.	0.9	7
89	EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence. BMC Cancer, 2018, 18, 1215.	1.1	13
90	Evidence-based Therapy and Problem of Glioblastoma. Japanese Journal of Neurosurgery, 2018, 27, 91-98.	0.0	0
91	Management of diffuse glioma. Presse Medicale, 2018, 47, e199-e212.	0.8	11
92	Targeting Long Noncoding RNA in Glioma: A Pathway Perspective. Molecular Therapy - Nucleic Acids, 2018, 13, 431-441.	2.3	47
93	Molecular classification of adult gliomas: recent advances and future perspectives. Current Opinion in Oncology, 2018, 30, 375-382.	1.1	7
94	Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma. NeuroMolecular Medicine, 2018, 20, 452-474.	1.8	18
96	Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 167-172.	0.6	17
97	Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Clinical Neurology and Neurosurgery, 2018, 170, 127-131.	0.6	8
98	Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged >75 years. International Journal of Clinical Oncology, 2018, 23, 820-825.	1.0	7
99	Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1263-1271.	0.6	15
100	Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014. Journal of Neuro-Oncology, 2018, 139, 479-489.	1.4	39
101	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 642-645.	2.3	9

#	ARTICLE	IF	CITATIONS
102	Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. <i>Acta Neurochirurgica</i> , 2018, 160, 1779-1787.	0.9	18
103	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. <i>Clinical Oncology</i> , 2018, 30, 556-562.	0.6	6
104	Clinical Pharmacology of Brain Tumor Chemotherapy. , 2018, , 21-44.		1
106	The Treatment of Gliomas in Adulthood. <i>Deutsches A&#x0308;rzteblatt International</i> , 2018, 115, 356-364.	0.6	20
107	Understanding and Treating Glioblastoma. <i>Neurologic Clinics</i> , 2018, 36, 485-499.	0.8	18
108	Hypofractionated and Stereotactic Radiation Therapy. , 2018, , .		2
109	Modern Techniques of Radiation Therapy in the Treatment of Brain Tumors and Tumors of the Skull Base. <i>Neurology International Open</i> , 2018, 2, E97-E107.	0.4	0
110	Treatment of Glioblastoma in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 707-718.	1.3	11
111	Primary brain tumours in adults. <i>Lancet, The</i> , 2018, 392, 432-446.	6.3	882
112	Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. <i>Journal of Neuro-Oncology</i> , 2018, 140, 329-339.	1.4	25
113	One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?. <i>Journal of Neuro-Oncology</i> , 2018, 140, 385-391.	1.4	31
114	Advances in Radiotherapy for Glioblastoma. <i>Frontiers in Neurology</i> , 2017, 8, 748.	1.1	103
115	The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis. <i>Frontiers in Neurology</i> , 2018, 9, 127.	1.1	36
116	Clinically Relevant Imaging Features for <i>MGMT</i> Promoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis. <i>American Journal of Neuroradiology</i> , 2018, 39, 1439-1445.	1.2	24
118	Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas â€“ a planning study. <i>Radiation Oncology</i> , 2018, 13, 31.	1.2	13
120	Natural products: a hope for glioblastoma patients. <i>Oncotarget</i> , 2018, 9, 22194-22219.	0.8	77
121	Treatment of glioblastoma in adults. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879045.	1.5	117
122	Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. <i>Journal of Neuro-Oncology</i> , 2018, 140, 421-426.	1.4	22

#	ARTICLE	IF	CITATIONS
123	Radiation Therapy in High-Grade Gliomas. , 2018, , 1-26.		0
124	Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 27-35.	0.6	6
125	Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. Journal of Neuroradiology, 2019, 46, 36-43.	0.6	14
126	Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori, 2019, 105, 47-54.	0.6	11
127	Utilization of hypofractionated radiation therapy in older glioblastoma patients. Journal of Geriatric Oncology, 2019, 10, 155-158.	0.5	5
128	Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme. Cancer Biomarkers, 2019, 25, 275-290.	0.8	26
129	Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma. Journal of Clinical Neuroscience, 2019, 68, 39-44.	0.8	17
130	Faculty of Radiation Oncology 2018 workforce census. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 852-861.	0.9	10
131	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Review of Neurotherapeutics, 2019, 19, 663-677.	1.4	3
132	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncology, 2019, 8, CNS32.	1.2	5
133	How we treat glioblastoma. ESMO Open, 2019, 4, e000520.	2.0	62
134	A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers. Current Treatment Options in Oncology, 2019, 20, 71.	1.3	19
135	Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. Journal of Contemporary Brachytherapy, 2019, 11, 215-220.	0.4	3
136	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiotherapy and Oncology, 2019, 138, 99-105.	0.3	34
137	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	0.6	49
138	Discovery of predictive biomarkers in malignant gliomas. Neuro-Oncology, 2019, 21, 1089-1090.	0.6	1
139	Glioblastoma Multiforme in the over 70's: â€œTo treat or not to treat with radiotherapy?â€• Cancer Medicine, 2019, 8, 4669-4677.	1.3	4
140	Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 1017.	1.3	14

#	ARTICLE	IF	CITATIONS
141	Treatment strategies for glioblastoma in older patients: age is just a number. <i>Journal of Neuro-Oncology</i> , 2019, 145, 357-364.	1.4	12
142	Geriatric assessment of glioblastoma patients is feasible and may provide useful prognostic information. <i>Neuro-Oncology Practice</i> , 2020, 7, 176-184.	1.0	5
143	Improved dosimetric accuracy with semi-automatic contour propagation of organs at risk in glioblastoma patients undergoing chemoradiation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 45-53.	0.8	7
144	Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged 75 years. <i>Radiation Oncology</i> , 2019, 14, 200.	1.2	19
145	Treatment of newly diagnosed glioblastoma in the elderly. <i>The Cochrane Library</i> , 0, , .	1.5	3
146	Management of Glioblastoma, Present and Future. <i>World Neurosurgery</i> , 2019, 131, 328-338.	0.7	39
147	Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. <i>Neuro-Oncology Practice</i> , 2019, 7, 164-175.	1.0	3
148	High-grade Glioma – A decade of care in Christchurch. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 665-673.	0.9	4
149	Patterns of Care After Surgery for Elderly Patients With Malignant Brain Tumors: Data from the National Health Insurance Service in South Korea. <i>Anticancer Research</i> , 2019, 39, 5733-5739.	0.5	2
151	Genetically Engineered Mouse Models of Gliomas: Technological Developments for Translational Discoveries. <i>Cancers</i> , 2019, 11, 1335.	1.7	31
152	Re-irradiation in elderly patients with glioblastoma: a single institution experience. <i>Journal of Neuro-Oncology</i> , 2019, 142, 327-335.	1.4	11
153	Central Nervous System Tumors. , 2019, , 1-41.		0
154	Comorbidities in elderly patients with glioblastoma: a field-practice study. <i>Future Oncology</i> , 2019, 15, 841-850.	1.1	12
155	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
156	Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. <i>Clinical and Translational Immunology</i> , 2019, 8, e1050.	1.7	33
157	Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience. <i>PLoS ONE</i> , 2019, 14, e0217881.	1.1	9
158	Genetic and molecular epidemiology of adult diffuse glioma. <i>Nature Reviews Neurology</i> , 2019, 15, 405-417.	4.9	437
159	Basic principles of brain tumor radiotherapy. , 2019, , 245-262.		1

#	ARTICLE	IF	CITATIONS
160	Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. <i>Neurosurgery</i> , 2019, 85, 441-453.	0.6	33
161	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. <i>World Neurosurgery</i> , 2019, 129, 90-100.	0.7	52
162	Radioterapia dei tumori cerebrali primitivi dell'adulto. <i>EMC - Neurologia</i> , 2019, 19, 1-11.	0.0	0
163	Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme. <i>BMJ Case Reports</i> , 2019, 12, e227500.	0.2	2
164	Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. <i>International Journal of Oncology</i> , 2019, 54, 2189-2199.	1.4	15
165	Glioblastoma. , 2019, , 237-247.		0
166	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. <i>Clinical Biochemistry</i> , 2019, 72, 15-23.	0.8	4
167	Effect of patient age on glioblastoma perioperative treatment costs: a value driven outcome database analysis. <i>Journal of Neuro-Oncology</i> , 2019, 143, 465-473.	1.4	12
168	Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation. <i>Journal of Geriatric Oncology</i> , 2019, 10, 770-778.	0.5	10
169	Epilepsy Associated with Glioma. , 2019, , 561-569.		0
170	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2019, 143, 447-455.	1.4	6
171	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 633-640.	0.9	19
172	Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?. <i>Neurochemical Research</i> , 2019, 44, 2392-2404.	1.6	33
173	Evidence-Based Practice: Temozolomide Beyond Glioblastoma. <i>Current Oncology Reports</i> , 2019, 21, 30.	1.8	39
174	Cost-effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas. <i>Radiology</i> , 2019, 291, 689-697.	3.6	29
175	Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 143, 177-185.	1.4	23
176	Glioblastoma in Elderly Patients: Current Management and Future Perspectives. <i>Cancers</i> , 2019, 11, 336.	1.7	62
177	<p><p>The surgical perspective in precision treatment of diffuse gliomas<p><p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1497-1508.	1.0	18

#	ARTICLE	IF	CITATIONS
178	Divining responder populations from survival data. <i>Annals of Oncology</i> , 2019, 30, 1005-1013.	0.6	9
179	The landscape of the mesenchymal signature in brain tumours. <i>Brain</i> , 2019, 142, 847-866.	3.7	228
180	MGMT Testing in Glioblastomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 117-122.	0.6	17
181	Improved treatment of glioblastoma “ changes in survival over two decades at a single regional Centre. <i>Acta OncolÃ³gica</i> , 2019, 58, 334-341.	0.8	20
182	Quality of Life in Brain Cancer: Clinical Validation of the Mexican-Spanish Version of the EORTC QLQ-BN20 Questionnaire. <i>Frontiers in Neurology</i> , 2019, 10, 40.	1.1	1
183	Tumors of the Central Nervous System: Therapeutic Approaches. , 2019, , 69-83.		0
184	Chemotherapy for Gliomas. , 2019, , 229-243.		0
185	Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. <i>BMJ Case Reports</i> , 2019, 12, e228803.	0.2	4
186	Screening and authentication of molecular markers in malignant glioblastoma based on gene expression profiles. <i>Oncology Letters</i> , 2019, 18, 4593-4604.	0.8	11
187	Temporalis muscle width as a measure of sarcopenia correlates with overall survival in patients with newly diagnosed glioblastoma. <i>Journal of Radiation Oncology</i> , 2019, 8, 379-387.	0.7	11
188	Neuroimaging for Radiation Therapy of Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 63-71.	0.7	9
189	Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. <i>Scientific Reports</i> , 2019, 9, 17794.	1.6	9
190	The Role of Particle Therapy for the Treatment of Skull Base Tumors and Tumors of the Central Nervous System (CNS). <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 49-61.	0.7	1
191	Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma. <i>NeuroReport</i> , 2019, 30, 1031-1038.	0.6	3
192	An audit of the management of elderly patients with glioblastoma in the UK: have recent trial results changed treatment?. <i>CNS Oncology</i> , 2019, 8, CNS47.	1.2	3
193	Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. <i>Radiation Oncology</i> , 2019, 14, 227.	1.2	6
194	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	0.6	173
197	Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era. <i>Neurosurgical Review</i> , 2019, 42, 937-950.	1.2	10

#	ARTICLE	IF	CITATIONS
198	Management of Adult Glioma in Nursing Practice. , 2019, , .		0
199	Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. <i>Neuro-Oncology</i> , 2019, 21, 370-379.	0.6	63
200	First validation of the G-8 geriatric screening tool in older patients with glioblastoma. <i>Journal of Geriatric Oncology</i> , 2019, 10, 159-163.	0.5	19
201	Association of patterns of care, prognostic factors, and use of radiotherapyâ€”temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. <i>Journal of Neuro-Oncology</i> , 2019, 142, 91-101.	1.4	52
202	Glioblastoma Therapy in the Age of Molecular Medicine. <i>Trends in Cancer</i> , 2019, 5, 46-65.	3.8	68
203	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	3.2	94
204	Down-regulation of 14-3-3zeta reduces proliferation and increases apoptosis in human glioblastoma. <i>Cancer Gene Therapy</i> , 2020, 27, 399-411.	2.2	12
205	Accrual of older adults to cancer clinical trials led by the Canadian cancer trials group â€” Is trial design a barrier?. <i>Journal of Geriatric Oncology</i> , 2020, 11, 455-462.	0.5	10
206	Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma. <i>Neuro-Oncology Practice</i> , 2020, 7, 68-76.	1.0	21
207	Inhibition of motility by NEO100 through the calpain-1/RhoA pathway. <i>Journal of Neurosurgery</i> , 2020, 133, 1020-1031.	0.9	4
208	Ongoing improvements in postoperative survival of glioblastoma in the temozolomide era: a population-based data linkage study. <i>Neuro-Oncology Practice</i> , 2020, 7, 22-30.	1.0	4
209	Neurocognitive evaluation in older adult patients affected by glioma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 701-708.	0.5	7
210	Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 58-69.	1.0	14
211	Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 3798-3814.	2.0	22
212	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. <i>Neuro-Oncology</i> , 2020, 22, 515-523.	0.6	140
213	Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit. <i>Journal of Neuro-Oncology</i> , 2020, 146, 381-387.	1.4	11
214	Survey of treatment recommendations for elderly patients with glioblastoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1329-1334.	1.2	4
215	Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 328-334.	0.8	24

#	ARTICLE	IF	CITATIONS
216	Long-term incidence of glioma in Olmsted County, Minnesota, and disparities in postglioma survival rate: a population-based study. <i>Neuro-Oncology Practice</i> , 2020, 7, 288-298.	1.0	9
217	Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 680-687.	0.5	6
218	Nanocarrier-based drug combination therapy for glioblastoma. <i>Theranostics</i> , 2020, 10, 1355-1372.	4.6	203
219	Clinical neuro-oncology for the neurologist. <i>Neurology: Clinical Practice</i> , 2020, 10, 458-465.	0.8	5
220	Tumor Board Report: The value of tissue diagnosis. <i>Current Problems in Cancer</i> , 2020, 44, 100530.	1.0	0
221	Optimal adjuvant therapy in elderly glioblastoma: results from a systematic review and network meta-analysis. <i>Journal of Neuro-Oncology</i> , 2020, 146, 311-320.	1.4	15
222	Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa126.	0.4	27
224	Cancer Stem Cells: New Horizons in Cancer Therapies. , 2020, , .		1
225	<p>Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9941-9952.	0.9	5
226	Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients. <i>NeuroImage: Clinical</i> , 2020, 28, 102427.	1.4	22
227	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	1.1	8
228	MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 855-862.	0.9	9
229	In regard to "Radiation for glioblastoma in the era of COVID-19: Patient selection and hypofractionation to maximize benefit and minimize risk". <i>Advances in Radiation Oncology</i> , 2020, 5, 746-747.	0.6	1
230	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. <i>Current Oncology Reports</i> , 2020, 22, 93.	1.8	6
231	Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. <i>Radiation Oncology</i> , 2020, 15, 264.	1.2	7
232	Frailty and outcomes after craniotomy for brain tumor. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 95-100.	0.8	39
233	Alkaloids of fascaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review. <i>International Review of Neurobiology</i> , 2020, 151, 299-324.	0.9	3
234	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. <i>Frontiers in Oncology</i> , 2020, 10, 840.	1.3	41

#	ARTICLE	IF	CITATIONS
235	Ca2+ as a therapeutic target in cancer. <i>Advances in Cancer Research</i> , 2020, 148, 233-317.	1.9	16
237	Temozolomide-induced aplastic anaemia: Case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522096708.	0.5	9
238	Geographic and socioeconomic considerations for glioblastoma treatment in the elderly at a national level: a US perspective. <i>Neuro-Oncology Practice</i> , 2020, 7, 522-530.	1.0	5
239	Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. <i>Scientific Reports</i> , 2020, 10, 18445.	1.6	20
240	Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?" <i>Neuro-Oncology</i> , 2020, 22, 1889-1890.	0.6	2
241	Next-generation DNA damage sequencing. <i>Chemical Society Reviews</i> , 2020, 49, 7354-7377.	18.7	56
242	The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 897.	1.1	26
243	Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma. <i>Frontiers in Oncology</i> , 2020, 10, 541401.	1.3	51
244	Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. <i>Acta Radiologica</i> , 2021, 62, 1200-1207.	0.5	6
245	Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow. <i>Journal of Neuro-Oncology</i> , 2020, 149, 305-314.	1.4	25
246	Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable. <i>Diagnostics</i> , 2020, 10, 676.	1.3	4
247	Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status. <i>Molecular Biology Reports</i> , 2020, 47, 7477-7488.	1.0	2
248	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	1.1	23
249	Establishment of age group classification for risk stratification in glioma patients. <i>BMC Neurology</i> , 2020, 20, 310.	0.8	59
250	Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 3553-3561.	0.5	5
251	Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). <i>Anticancer Research</i> , 2020, 40, 7025-7030.	0.5	3
252	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa082.	0.4	29
253	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. <i>NeurocirugÃa (English Edition)</i> , 2020, 31, 289-297.	0.1	2

#	ARTICLE	IF	CITATIONS
254	Consenso sobre guías de tratamiento de los glioblastomas elaborado por el Grupo de Trabajo de Neurooncología (GTNO) de la SENEC. Neurocirugía, 2020, 31, 289-298.	0.2	4
255	The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme. Cancers, 2020, 12, 1099.	1.7	26
256	Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?. Journal of Neuro-Oncology, 2020, 148, 57-65.	1.4	13
257	Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas. Neuro-Oncology, 2020, 22, 928-935.	0.6	62
258	Genomics models in radiotherapy: From mechanistic to machine learning. Medical Physics, 2020, 47, e203-e217.	1.6	17
259	Treatment options for recurrent glioblastoma: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
260	External beam radiation dose escalation for high grade glioma. The Cochrane Library, 2020, 2020, CD011475.	1.5	12
261	A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. Radiation Oncology, 2020, 15, 97.	1.2	15
262	Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?. Neuro-Oncology, 2020, 22, 1058-1059.	0.6	1
263	Management of glioblastoma: State of the art and future directions. Ca-A Cancer Journal for Clinicians, 2020, 70, 299-312.	157.7	969
264	Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk. Advances in Radiation Oncology, 2020, 5, 743-745.	0.6	12
265	High Levels of HIST1H2BK in Low-Grade Glioma Predicts Poor Prognosis: A Study Using CGGA and TCGA Data. Frontiers in Oncology, 2020, 10, 627.	1.3	22
266	Nanomedicine-based immunotherapy for central nervous system disorders. Acta Pharmacologica Sinica, 2020, 41, 936-953.	2.8	38
267	Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. Journal of Neuro-Oncology, 2020, 148, 473-480.	1.4	2
268	Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. Journal of Neuro-Oncology, 2020, 147, 297-307.	1.4	116
269	Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma. Frontiers in Oncology, 2020, 10, 208.	1.3	47
270	Predictive Analyses of Prognostic-Related Immune Genes and Immune Infiltrates for Glioblastoma. Diagnostics, 2020, 10, 177.	1.3	15
271	The Nomogram Model Predicting Overall Survival and Guiding Clinical Decision in Patients With Glioblastoma Based on the SEER Database. Frontiers in Oncology, 2020, 10, 1051.	1.3	22

#	ARTICLE	IF	CITATIONS
272	Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa046.	0.4	7
273	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060.	0.4	8
274	Novel CXCR4 Inhibitor CPZ1344 Inhibits the Proliferation, Migration and Angiogenesis of Glioblastoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2597-2604.	0.9	6
275	Disparities in patient enrollment on glioblastoma clinical trials. <i>CNS Oncology</i> , 2020, 9, CNS59.	1.2	3
276	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 65-71.	1.4	14
277	A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. <i>Neuro-Oncology</i> , 2020, 22, 1182-1189.	0.6	30
278	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1486-1495.	3.3	16
279	Heme Oxygenase-1 and Carbon Monoxide Regulate Growth and Progression in Glioblastoma Cells. <i>Molecular Neurobiology</i> , 2020, 57, 2436-2446.	1.9	25
280	Patterns of management and outcomes of unifocal versus multifocal glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 155-159.	0.8	20
281	Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma—results of a multicenter study. <i>Supportive Care in Cancer</i> , 2020, 28, 5165-5175.	1.0	11
282	Disparities in glioblastoma survival by case volume: a nationwide observational study. <i>Journal of Neuro-Oncology</i> , 2020, 147, 361-370.	1.4	14
283	Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. <i>Theranostics</i> , 2020, 10, 3223-3239.	4.6	59
284	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172.	0.6	42
285	Management of glioblastoma: an Australian perspective. <i>Chinese Clinical Oncology</i> , 2021, 10, 42-42.	0.4	5
286	Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients. <i>PLoS ONE</i> , 2020, 15, e0228480.	1.1	9
287	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 685.	1.8	18
288	Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status. <i>Journal of Neuro-Oncology</i> , 2020, 147, 91-95.	1.4	1
289	Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2664-2672.	3.2	21

#	ARTICLE	IF	CITATIONS
290	Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 457-464.	1.0	8
291	First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. <i>Journal of Neuro-Oncology</i> , 2020, 146, 451-458.	1.4	16
292	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	0.6	15
293	Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. <i>Cancer</i> , 2020, 126, 3255-3264.	2.0	19
295	Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD013261.	1.5	37
296	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , 2020, 36, 429-441.	2.9	58
297	Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4318-4330.	2.9	33
298	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. <i>Neuro-Oncology</i> , 2020, 22, 912-917.	0.6	59
299	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
300	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	0.6	64
301	Management of glioblastomas in the elderly population. <i>Revue Neurologique</i> , 2020, 176, 724-732.	0.6	4
302	Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications. , 2020, 11, 448.		15
303	Overview of prognostic factors in adult gliomas. <i>Annals of Palliative Medicine</i> , 2021, 10, 863-874.	0.5	34
304	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 253-262.	1.2	8
305	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	0.5	5
306	Chemotherapy toxicities and geriatric syndromes in older patients with malignant gliomas. <i>Journal of Geriatric Oncology</i> , 2021, 12, 134-138.	0.5	6
307	Narrative review of palliative hypofractionated radiotherapy for high grade glioma. <i>Annals of Palliative Medicine</i> , 2021, 10, 846-862.	0.5	5
308	Importance and Evidence of Extent of Resection in Glioblastoma. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2021, 82, 075-086.	0.4	18

#	ARTICLE	IF	CITATIONS
309	Surgery for Glioblastoma in Elderly Patients. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 137-148.	0.8	5
310	Nestin+/CD31+ cells in the hypoxic perivascular niche regulate glioblastoma chemoresistance by upregulating JAG1 and DLL4. <i>Neuro-Oncology</i> , 2021, 23, 905-919.	0.6	14
311	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
312	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
313	Update on the management of elderly patients with glioblastoma: a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 899-908.	0.5	2
314	Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. <i>World Neurosurgery</i> , 2021, 146, e755-e767.	0.7	7
315	The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. <i>Radiotherapy and Oncology</i> , 2021, 156, 49-55.	0.3	2
316	Real-world evaluation of the impact of radiotherapy and chemotherapy in elderly patients with glioblastoma based on age and performance status. <i>Neuro-Oncology Practice</i> , 2021, 8, 199-208.	1.0	9
317	Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy. <i>Journal of NeuroVirology</i> , 2021, 27, 94-100.	1.0	2
318	Predictors of survival in elderly patients undergoing surgery for glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab083.	0.4	7
319	Recent incidence trend of elderly patients with glioblastoma in the United States, 2000â€“2017. <i>BMC Cancer</i> , 2021, 21, 54.	1.1	36
321	Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013579.	1.5	46
322	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
323	Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. <i>BMC Cancer</i> , 2021, 21, 81.	1.1	22
324	Glioblastoma. <i>Practical Guides in Radiation Oncology</i> , 2021, , 107-111.	0.0	0
325	Introduction to radiation therapy. , 2021, , 28-37.		0
326	Glioblastoma. , 2021, , 215-230.		0
327	Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields. <i>Journal of Cancer</i> , 2021, 12, 1094-1104.	1.2	12

#	ARTICLE	IF	CITATIONS
328	A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. <i>Anticancer Research</i> , 2021, 41, 379-384.	0.5	2
329	The Role of Molecular Genetics of Glioblastoma in the Clinical Setting. <i>Molecular Pathology Library</i> , 2021, , 21-33.	0.1	0
330	Radiology in the lead: towards radiological profiling for precision medicine in glioblastoma patients? Editorial comment on Glioblastoma patients with a moderate vascular profile benefit the most from MGMT methylation. <i>European Radiology</i> , 2021, 31, 1736-1737.	2.3	2
331	Past and present drug treatments for glioblastoma. , 2021, , 17-29.		0
332	Principles of Radiation Therapy for Glioblastoma Patients. <i>Molecular Pathology Library</i> , 2021, , 91-103.	0.1	0
333	Neuro-Oncologic Care During the COVID-19 Pandemic. , 2021, , 123-129.		0
334	The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. <i>British Journal of Neurosurgery</i> , 2021, , 1-13.	0.4	1
335	A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 87-100.	1.5	9
336	Approaching glioblastoma during COVID-19 pandemic: current recommendations and considerations in Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 167-172.	0.3	5
337	The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. <i>Cells</i> , 2021, 10, 484.	1.8	73
338	Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. <i>Cancer Research</i> , 2021, 81, 2220-2233.	0.4	19
339	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	1.3	0
340	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021, 145, 171-178.	1.3	7
341	Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). <i>Brain Sciences</i> , 2021, 11, 386.	1.1	14
342	Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells. <i>Brain Pathology</i> , 2021, 31, e12947.	2.1	16
343	Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 587554.	1.3	34
344	Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence. <i>Cancers</i> , 2021, 13, 1560.	1.7	14
345	Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System. <i>Current Drug Targets</i> , 2021, 22, 429-442.	1.0	9

#	ARTICLE	IF	CITATIONS
346	Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway. <i>BMJ Open</i> , 2021, 11, e043208.	0.8	14
347	Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3381-3390.	1.2	16
348	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2960.	1.8	4
349	Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. <i>Journal of Biomedical Science</i> , 2021, 28, 18.	2.6	42
350	Current FDA-Approved Therapies for High-Grade Malignant Gliomas. <i>Biomedicines</i> , 2021, 9, 324.	1.4	125
351	Advanced Imaging Techniques for Radiotherapy Planning of Gliomas. <i>Cancers</i> , 2021, 13, 1063.	1.7	31
352	Novel Radiation Approaches. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 211-223.	0.8	7
353	Diagnosis and Management of Glioblastoma: A Comprehensive Perspective. <i>Journal of Personalized Medicine</i> , 2021, 11, 258.	1.1	23
354	Topography of transcriptionally active chromatin in glioblastoma. <i>Science Advances</i> , 2021, 7, .	4.7	19
355	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , 2021, 39, 509-528.e20.	7.7	327
356	The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2021, 148, e565-e571.	0.7	2
357	Patients and carers' perspectives of participating in a pilot tailored exercise program during chemoradiotherapy for high grade glioma: A qualitative study. <i>European Journal of Cancer Care</i> , 2021, 30, e13453.	0.7	8
358	Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021, 5, 346-359.	11.6	13
359	Competing risk model to determine the prognostic factors and treatment strategies for elderly patients with glioblastoma. <i>Scientific Reports</i> , 2021, 11, 9321.	1.6	12
360	High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 650534.	1.3	15
361	Upregulation of lnc-ZNF281 Inhibits the Progression of Glioma via the AKT/GSK-3 β / β -Catenin Signaling Pathway. <i>Journal of Immunology Research</i> , 2021, 2021, 1-9.	0.9	1
362	Rediscovering Potential Molecular Targets for Glioma Therapy Through the Analysis of the Cell of Origin, Microenvironment and Metabolism. <i>Current Cancer Drug Targets</i> , 2021, 21, 558-574.	0.8	7
363	Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report. <i>Frontiers in Nutrition</i> , 2021, 8, 682243.	1.6	13

#	ARTICLE	IF	CITATIONS
364	The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type <i>IDH</i> , Unmethylated <i>MGMT</i> Glioblastoma During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2021, 7, 675.	3.4	16
365	Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma). <i>International Journal of Clinical Oncology</i> , 2021, 26, 1441-1449.	1.0	3
366	Parenteral high-dose ascorbate - A possible approach for the treatment of glioblastoma (Review). <i>International Journal of Oncology</i> , 2021, 58, .	1.4	8
367	Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2021, 149, e1026-e1037.	0.7	6
368	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated <i>MGMT</i> glioblastoma: the VERTU study. <i>Neuro-Oncology</i> , 2021, 23, 1736-1749.	0.6	44
369	The clinical and prognostic role of <i>ALK</i> in glioblastoma. <i>Pathology Research and Practice</i> , 2021, 221, 153447.	1.0	5
370	Limited recurrence distance of glioblastoma under modern radiotherapy era. <i>BMC Cancer</i> , 2021, 21, 720.	1.1	13
371	A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. <i>Nano Letters</i> , 2021, 21, 5158-5166.	4.5	14
372	A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells. <i>Molecules</i> , 2021, 26, 3383.	1.7	13
373	Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era. <i>Journal of Clinical Neuroscience</i> , 2021, 88, 120-127.	0.8	2
374	Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. <i>Current Oncology</i> , 2021, 28, 2399-2408.	0.9	4
375	Determining optimal clinical target volume margins in high-grade glioma based on microscopic tumor extension and magnetic resonance imaging. <i>Radiation Oncology</i> , 2021, 16, 97.	1.2	5
376	CHANGES IN THE <i>MGMT</i> GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND <i>MGMT</i> EXPRESSION ON SURVIVAL OF PATIENTS. <i>Siberian Journal of Oncology</i> , 2021, 20, 5-17.	0.1	2
377	Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4105-4115.	3.3	18
379	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
380	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1983-1994.	0.9	2
381	Bioinformatics Analysis of Expression Profiles and Prognostic Values of the Signal Transducer and Activator of Transcription Family Genes in Glioma. <i>Frontiers in Genetics</i> , 2021, 12, 625234.	1.1	12
382	The prognosis of glioblastoma: a large, multifactorial study. <i>British Journal of Neurosurgery</i> , 2021, 35, 555-561.	0.4	28

#	ARTICLE	IF	CITATIONS
383	Neurocytological Advances in the Treatment of Glioblastoma Multiforme. <i>Cureus</i> , 2021, 13, e16301.	0.2	2
385	Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?. <i>Neuro-Oncology</i> , 2021, 23, 1616-1618.	0.6	0
387	Multimodal Role of PACAP in Glioblastoma. <i>Brain Sciences</i> , 2021, 11, 994.	1.1	9
388	Glioblastoma: clinical presentation, diagnosis, and management. <i>BMJ, The</i> , 2021, 374, n1560.	3.0	133
389	The need for geriatric scales in glioblastoma. <i>Aging</i> , 2021, 13, 17959-17960.	1.4	0
390	Exosomal noncoding RNAs: key players in glioblastoma drug resistance. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 4081-4092.	1.4	30
391	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103372.	2.0	19
392	Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression. <i>European Journal of Radiology</i> , 2021, 144, 109941.	1.2	6
393	Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 194-208.	2.8	31
394	Radiotherapy for glioblastoma patients with poor performance status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2127-2136.	1.2	2
396	Age influences the distribution of diffuse gliomas. <i>Aging</i> , 2021, 13, 19083-19084.	1.4	0
397	Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. <i>Oncologist</i> , 2021, 26, 950-955.	1.9	19
398	Multifocal high-grade glioma radiotherapy safety and efficacy. <i>Radiation Oncology</i> , 2021, 16, 165.	1.2	11
400	Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States. <i>Frontiers in Pharmacology</i> , 2021, 12, 743979.	1.6	2
401	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). <i>European Journal of Cancer</i> , 2021, 154, 46-56.	1.3	10
402	Changes of Healthy Brain Tissue after Salvage Radiotherapy of Glioblastoma Multiforme. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab139.	0.4	0
404	Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells. <i>Pharmacological Research</i> , 2021, 171, 105764.	3.1	30
405	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.	1.7	10

#	ARTICLE	IF	CITATIONS
406	Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111928.	2.5	28
407	Biomimetic and cell-based nanocarriers “ New strategies for brain tumor targeting. <i>Journal of Controlled Release</i> , 2021, 337, 482-493.	4.8	27
408	Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. <i>CNS Oncology</i> , 2021, 10, CNS74.	1.2	8
409	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 671972.	1.3	14
410	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
411	Comprehensive ability evaluation and trend analysis of patients with malignant intracranial tumors in the perisurgery period. <i>Brain and Behavior</i> , 2021, 11, e02192.	1.0	3
412	Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 371-384.	0.4	18
413	Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis. <i>Medicine (United States)</i> , 2021, 100, e23513.	0.4	8
415	Mechano-Biological Features in a Patient-Specific Computational Model of Glioblastoma. <i>Neuromethods</i> , 2021, , 265-287.	0.2	1
417	Newly diagnosed glioblastoma in geriatric (65%+) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. <i>Journal of Neuro-Oncology</i> , 2020, 149, 421-427.	1.4	20
418	Genomic Biomarker Assessment in Gliomas. <i>Surgical Pathology Clinics</i> , 2020, 13, 209-215.	0.7	4
419	Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells. <i>Scientific Reports</i> , 2020, 10, 22185.	1.6	10
420	<i>In silico</i> identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma. <i>Bioscience Reports</i> , 2020, 40, .	1.1	12
421	Lnc GNG12-AS1 knockdown suppresses glioma progression through the AKT/GSK-3 β -catenin pathway. <i>Bioscience Reports</i> , 2020, 40, .	1.1	13
422	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	0.6	23
423	Adult Gliomas. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1452-1475.	0.4	8
424	Current Standards of Care in Glioblastoma Therapy. , 0, , 197-241.		114
425	Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. <i>Aging</i> , 2018, 10, 592-605.	1.4	311

#	ARTICLE	IF	CITATIONS
426	Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma. <i>Aging</i> , 2019, 11, 9405-9423.	1.4	13
427	D-galactose induces senescence of glioblastoma cells through YAP-CDK6 pathway. <i>Aging</i> , 2020, 12, 18501-18521.	1.4	23
428	Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts. <i>Translational Cancer Research</i> , 2018, 7, S802-S805.	0.4	9
429	<p>Identification of Aberrantly Expressed Genes in Murine Glioblastoma During Radiotherapy via Bioinformatic Data Mining</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3839-3851.	1.0	3
430	Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 600-611.	1.0	2
431	The algorithms of adjuvant therapy in gliomas and their effect on survival. <i>Journal of Neurosurgical Sciences</i> , 2019, 63, 179-186.	0.3	5
432	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 225-238.	0.4	18
433	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. <i>Neurosurgical Focus</i> , 2020, 49, E11.	1.0	4
434	Cancer care and COVID-19: tailoring recommendations for the African radiation oncology context. <i>Ecancermedalscience</i> , 2020, 14, 1144.	0.6	10
435	ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics. <i>Neurology India</i> , 2020, 68, 769.	0.2	8
436	Management of glioma patients during the coronavirus disease 2019 pandemic. <i>Glioma (Mumbai, India)</i> , 2020, 3, 31.	0.0	2
437	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	2.3	253
438	Management of Gliomas: Individualized Treatment Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 985-988.	2.3	2
439	Performance Status Restriction in Phase III Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1322-1326.	2.3	18
440	Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme. <i>Cureus</i> , 2017, 9, e1388.	0.2	3
441	Surgical strategies for older patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 155, 255-264.	1.4	9
442	A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). <i>BMC Cancer</i> , 2021, 21, 1105.	1.1	6
443	The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas. <i>IScience</i> , 2021, 24, 103249.	1.9	5

#	ARTICLE	IF	CITATIONS
444	Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab153.	0.4	8
445	Update on Radiation Therapy for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 77-93.	0.9	5
447	High-Grade Gliomas. , 2018, , 83-102.		0
448	Glioblastoma. , 2018, , 117-125.		0
450	Glioblastoma in older adults. <i>Aging</i> , 2018, 10, 154-155.	1.4	0
451	Giant Glioblastoma in a Patient with Previous Prostate Adenocarcinoma. <i>Advancements in Case Studies</i> , 2018, 1, .	0.1	0
453	ZNS-Tumoren. , 2019, , 215-235.		0
454	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
455	Age: A Criterion to Offer Surgical Treatment as a Cyoreductive Tool for Malignant Primary Brain Tumour?. , 2019, , 41-54.		0
456	Central Nervous System Cancers. , 2019, , 83-131.		1
457	Neuropsychological Assessment of Older Adults with a History of Cancer. <i>Clinical Handbooks in Neuropsychology</i> , 2019, , 427-442.	0.1	0
458	Gliome. <i>Springer Reference Medizin</i> , 2019, , 1-14.	0.0	0
459	Gliome. <i>Springer Reference Medizin</i> , 2020, , 1-14.	0.0	0
460	Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. <i>Korean Journal of Radiology</i> , 2020, 21, 471.	1.5	5
461	Tumors: Brain. , 2020, , 1-8.		0
462	Modern Treatments for Gliomas Improve Outcome. <i>Current Cancer Therapy Reviews</i> , 2020, 16, 221-245.	0.2	0
463	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. <i>Cancers</i> , 2021, 13, 5420.	1.7	6
464	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 113-132.	0.9	2

#	ARTICLE	IF	CITATIONS
465	Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis. International Journal of Experimental Pathology, 2021, 102, 232-241.	0.6	3
466	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. Japanese Journal of Neurosurgery, 2020, 29, 188-197.	0.0	0
467	Neuroonkologie. , 2020, , 257-271.		0
468	Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas. Translational Cancer Research, 2020, 9, 7642-7651.	0.4	0
469	Chemotherapy for Brain Tumors. , 2021, , 357-383.		0
470	Gliome des Erwachsenenalters. Springer Reference Medizin, 2021, , 1-12.	0.0	0
471	Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdaa171.	0.4	4
472	Gliome. Springer Reference Medizin, 2020, , 997-1010.	0.0	0
474	Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review. International Review of Neurobiology, 2020, 151, 67-98.	0.9	2
475	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
476	Advancement of clinical therapeutic research on glioma: A narrative review. Glioma (Mumbai, India), 2020, 3, 119.	0.0	1
477	Tumeurs cérébrales, gliomes malins. , 2020, , 227-237.e2.		0
478	Current Status of Glioblastoma Treatment. Advances in Clinical Medicine, 2020, 10, 2875-2882.	0.0	0
479	Malignome des zentralen Nervensystems (ZNS). , 2020, , 1021-1055.		0
480	Staging and Target Volume Definition by Imaging in CNS Tumors. Medical Radiology, 2020, , 151-168.	0.0	0
481	Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches. Journal of Pharmaceutical Investigation, 2022, 52, 49-74.	2.7	25
482	Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis. PLoS ONE, 2021, 16, e0257384.	1.1	6
483	Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide. Journal of Personalized Medicine, 2021, 11, 1145.	1.1	11

#	ARTICLE	IF	CITATIONS
484	Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging. <i>Brain Communications</i> , 2021, 3, fcab264.	1.5	5
485	Neues zur Diagnostik und Therapie von Gliomen. <i>Neuroradiologie Scan</i> , 2020, 10, 199-214.	0.0	0
486	The Ever Changing Treatments for Tumors of the Central Nervous System. <i>Current Cancer Therapy Reviews</i> , 2020, 16, 166-167.	0.2	0
487	Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa159.	0.4	7
488	Long noncoding RNA ZEB1-AS1 promotes the tumorigenesis of glioma cancer cells by modulating the miR-200c/141-ZEB1 axis. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 3395-3412.	0.0	31
489	Newly Diagnosed Glioblastoma: A Review on Clinical Management. <i>Oncology</i> , 2019, 33, 91-100.	0.4	42
490	'Editors' Choice' Impact of maintenance of postoperative performance status on survival in elderly patients over 70 with high-grade astrocytoma. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 533-543.	0.6	0
491	Gliome. , 2022, , 448-454.		0
492	Hypofractionated radiotherapy results of patients with malign glioma aged 60 and over. <i>Journal of Health Sciences and Medicine</i> , 2021, 4, 871-875.	0.0	0
493	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. <i>Scientific Reports</i> , 2021, 11, 22057.	1.6	1
494	Frailty in Glioblastoma Is Independent From Chronological Age. <i>Frontiers in Neurology</i> , 2021, 12, 777120.	1.1	8
496	Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients. <i>Frontiers in Neuroscience</i> , 2021, 15, 782516.	1.4	6
497	Tumors: Brain. , 2021, , 5208-5215.		0
498	Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab171.	0.4	8
499	Management of Glioblastoma Multiforme as a Big Challenge for Neurosurgeons and Radiation Oncologists in Covid-19 Era: An Institutional Experience in a Rural Sub-Himalayan Region. <i>Journal of Surgery and Surgical Research</i> , 2020, , 152-155.	0.1	1
500	Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 156, 407-417.	1.4	0
501	Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (>=70 years) glioblastoma patients: a preliminary analysis. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac007.	0.4	3
502	Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 499-507.	1.4	1

#	ARTICLE	IF	CITATIONS
503	Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. <i>Journal of Neuro-Oncology</i> , 2022, 156, 579-588.	1.4	5
504	Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 726561.	1.1	6
505	Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management. <i>Current Oncology</i> , 2022, 29, 360-376.	0.9	11
506	Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies. <i>Biomaterials Science</i> , 2022, 10, 892-908.	2.6	19
507	Preoperative Stereotactic Radiosurgery for Glioblastoma. <i>Biology</i> , 2022, 11, 194.	1.3	7
508	Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 913-926.	0.8	2
509	Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. <i>Journal of Cancer</i> , 2022, 13, 354-363.	1.2	13
510	Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 399-406.	1.4	6
511	Multidisciplinary Treatment for Glioblastoma. <i>Japanese Journal of Neurosurgery</i> , 2022, 31, 11-19.	0.0	0
512	The effectiveness of gamma knife radiosurgery for the management of residual high-grade gliomas: A single institutional study. <i>Journal of Clinical Neuroscience</i> , 2022, 95, 159-163.	0.8	1
513	Prognostic and Predictive Factors in Elderly Patients With Glioblastoma: A Single-Center Retrospective Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 777962.	1.7	6
514	Metastatic gastroesophageal cancer in older patients “ is this patient cohort represented in clinical trials?. <i>BMC Cancer</i> , 2022, 22, 3.	1.1	3
515	Retrospective single-center study on elderly patients with glioblastoma between 2014 and 2018 evaluating the effect of age and performance status on survival. <i>Neuro-Oncology Practice</i> , 2022, 9, 142-148.	1.0	1
517	Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?. <i>BMC Neurology</i> , 2022, 22, 32.	0.8	7
518	Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay. <i>Journal of Biomedical Physics and Engineering</i> , 2022, 12, 43-50.	0.5	2
519	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	0.8	67
520	Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 135-144.	1.0	2
521	Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 12.	0.4	6

#	ARTICLE	IF	CITATIONS
522	Newly Diagnosed Glioblastoma in Elderly Patients. <i>Current Oncology Reports</i> , 2022, 24, 325-334.	1.8	3
524	Radiation guidelines for gliomas. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 116-128.	0.6	3
525	Natural Products as an Alternative Therapy for Brain Tumors. , 2022, , 1-26.		0
526	Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2022, 8, 6.	0.3	0
527	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	1.7	3
528	Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma. <i>World Neurosurgery</i> , 2022, 161, e448-e463.	0.7	5
529	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	1.2	25
530	Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India. <i>World Neurosurgery</i> , 2022, , .	0.7	1
531	Analytic approaches to clinical validation of results from preclinical models of glioblastoma: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0264740.	1.1	3
532	Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study. <i>World Neurosurgery</i> , 2022, 159, e479-e487.	0.7	2
533	The Combined Use of 5-ALA and Chlorin e6 Photosensitizers for Fluorescence-Guided Resection and Photodynamic Therapy under Neurophysiological Control for Recurrent Glioblastoma in the Functional Motor Area after Ineffective Use of 5-ALA: Preliminary Results. <i>Bioengineering</i> , 2022, 9, 104.	1.6	8
534	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome including in elderly patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 39.	2.4	6
535	Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials. <i>Cancer</i> , 2022, 128, 2367-2374.	2.0	4
536	Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects. <i>Biomedicines</i> , 2022, 10, 644.	1.4	12
537	Safe surgery for glioblastoma: Recent advances and modern challenges. <i>Neuro-Oncology Practice</i> , 2022, 9, 364-379.	1.0	14
538	Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation study. <i>Neuro-Oncology Advances</i> , 2022, 4, vda038.	0.4	6
539	Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. <i>Seminars in Radiation Oncology</i> , 2022, 32, 125-134.	1.0	7
540	Hypofractionation in Older Adults With Glioblastoma. <i>Seminars in Radiation Oncology</i> , 2022, 32, 168-171.	1.0	1

#	ARTICLE	IF	CITATIONS
541	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
542	Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy. <i>Neoplasia</i> , 2022, 26, 100779.	2.3	7
543	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	3.2	27
544	Effectiveness of different treatment strategies in elderly patients with glioblastoma: An evidence map of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103645.	2.0	4
545	Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 667884.	1.3	9
546	Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Population-Based Analysis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9523-9536.	0.8	5
547	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	0.6	13
548	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022, 24, 358-383.	0.6	1
549	Optimizing management of the elderly patient with glioblastoma: Survival prediction online tool based on BC Cancer Registry real-world data. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	2
550	Radiation Therapy in Older Adults With Cancer: A Critical Modality in Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 1806-1811.	0.8	7
551	MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 561-571.	1.4	5
552	Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis. <i>Brain Sciences</i> , 2022, 12, 501.	1.1	7
580	Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21â€™05). <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 843-849.	0.6	1
581	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1665-1673.	1.9	16
583	Is Mini Beam Ready for Human Trials? Results of Randomized Study of Treating De-Novo Brain Tumors in Canines Using Linear Accelerator Generated Mini Beams. <i>Radiation Research</i> , 2022, 198, .	0.7	3
584	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5238.	1.8	4
585	Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). <i>Journal of Neuro-Oncology</i> , 2022, 158, 349-357.	1.4	10
587	Elderly Glioblastoma Patients: The Impact of Surgery and Adjuvant Treatments on Survival: A Single Institution Experience. <i>Brain Sciences</i> , 2022, 12, 632.	1.1	11

#	ARTICLE	IF	CITATIONS
588	Opportunities and Advances in the use of Proton Radiotherapy for Management of Central Nervous System and Base of Skull Tumors. <i>Advances in Oncology</i> , 2022, 2, 1-11.	0.1	1
589	Optimal managements of elderly patients with glioblastoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 833-842.	0.6	2
590	Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. <i>CNS Oncology</i> , 2022, 11, .	1.2	5
591	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	2.1	26
592	Gamma Irradiation Triggers Immune Escape in Glioma-Propagating Cells. <i>Cancers</i> , 2022, 14, 2728.	1.7	1
593	Non-stereotactic radiotherapy in older cancer patients. <i>Heliyon</i> , 2022, 8, e09593.	1.4	3
594	lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PI3K/AKT pathway in glioma. <i>Cancer Science</i> , 2022, 113, 2681-2692.	1.7	18
595	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. <i>British Journal of Cancer</i> , 2022, 127, 976-987.	2.9	26
596	The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120316.	0.3	10
597	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. , 2022, 39, .		8
598	Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. <i>Pharmacological Research</i> , 2022, 182, 106316.	3.1	3
599	Genomic Landscape and Immunological Profile of Glioblastoma in East Asians. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
600	A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. <i>Neurographics</i> , 2022, 12, 43-70.	0.0	3
601	Converging Mechanisms of Epileptogenesis and Their Insight in Glioblastoma. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	9
602	The Network of Tumor Microtubes: An Improperly Reactivated Neural Cell Network With Stemness Feature for Resistance and Recurrence in Gliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
603	Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma. <i>Oncogene</i> , 0, , .	2.6	0
604	MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7148.	1.8	18
605	Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
606	Eukaryotic Extension Factor 2 Kinase may Affect the Occurrence and Development of Glioblastoma Through Immune Cell Infiltration. <i>Neurochemical Research</i> , 0, , .	1.6	0
607	Butterfly glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-based cohort. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	2
608	Glioblastoma " treatment and obstacles. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	6
609	Refined efficacy and outcome estimates of surgical treatment in oldest-old patients with glioblastomas based on competing risk model and conditional survival analysis: A surveillance, epidemiology, and end results population-based study. <i>Clinical Neurology and Neurosurgery</i> , 2022, 221, 107391, .	0.6	2
610	Is there a limited value of cytoreductive surgery in elderly patients with malignant gliomas?. , 0, 13, 320.		0
611	Emergency surgical decompression and long-term survival of glioblastoma presenting in coma in old age: case report and review of prognostic factors. <i>Oxford Medical Case Reports</i> , 2022, 2022, .	0.2	0
612	Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113416.	2.5	5
613	Characteristics and trends of globally registered glioma clinical trials in the past 16 years. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211143.	1.5	1
614	A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSK-010 trial protocol. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
615	Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
616	A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM). <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2317-2323.	0.5	1
618	Glioblastoma in Elderly Population. , 0, , .		0
619	Emerging immune-based technologies for high-grade gliomas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 957-980.	1.1	1
620	Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
621	Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable. <i>Pharmaceutics</i> , 2022, 14, 1697.	2.0	7
622	The role of NCAPG in various of tumors. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113635.	2.5	7
623	Comparison of Prospectively Generated Glioma Treatment Plans Clinically Delivered on Magnetic Resonance Imaging (MRI)-Linear Accelerator (MR-Linac) Versus Conventional Linac: Predicted and Measured Skin Dose. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211246.	0.8	4
624	Natural Products as an Alternative Therapy for Brain Tumors. , 2022, , 653-677.		0

#	ARTICLE	IF	CITATIONS
625	Metabolomics in High Grade Gliomas. <i>RAS Oncology & Therapy</i> , 2022, 3, .	0.1	0
626	Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive study. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	0
627	A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). <i>Oncology Reports</i> , 2022, 48, .	1.2	7
628	Galangin (GLN) Promotes Temozolomide-Induced Apoptosis in Glioma Cells. <i>Biology Bulletin</i> , 2022, 49, 580-587.	0.1	2
629	Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis. <i>Communications Biology</i> , 2022, 5, .	2.0	2
630	Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
631	Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
632	Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma. <i>BMJ Open</i> , 2022, 12, e058107.	0.8	2
633	Mechanism and Function of Circular RNA in Regulating Solid Tumor Radiosensitivity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10444.	1.8	1
634	Current therapeutic options for glioblastoma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1629-1640.	0.9	5
635	Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
636	Recurrent glioblastoma in elderly: Options and decision for the treatment. , 0, 13, 397.		6
637	Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas â€“ a retrospective population based study. <i>BMC Geriatrics</i> , 2022, 22, .	1.1	1
638	Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
639	Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
640	Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues dâ€™Expression FranÃ§aise (ANOCEF) trial. <i>Journal of Neurosurgery</i> , 2022, , 1-7.	0.9	3
641	The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	13
642	Radiotherapy utilisation rates for patients with cancer as a function of age: A systematic review. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101387.	0.5	1

#	ARTICLE	IF	CITATIONS
643	Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series. Journal of Oncology, 2022, 2022, 1-10.	0.6	0
644	The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. International Journal of Molecular Sciences, 2022, 23, 13034.	1.8	2
646	Glioma stem cells and neural stem cells respond differently to BMP4 signaling. Cell Regeneration, 2022, 11, .	1.1	0
647	Application of biomaterials for glioblastoma treatment: Promises, advances, and challenges. Materials Today Communications, 2022, 33, 104562.	0.9	0
648	Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. Journal of Neuro-Oncology, 2022, 160, 361-374.	1.4	2
649	Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
650	The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. International Journal of Molecular Sciences, 2022, 23, 13577.	1.8	8
652	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. Frontiers in Oncology, 0, 12, .	1.3	0
653	Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients. Frontiers in Neurology, 0, 13, .	1.1	0
654	Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study. Cancers, 2022, 14, 5509.	1.7	2
655	Quality of life in glioblastoma after the introduction of temozolomide: a systematic review. Research, Society and Development, 2022, 11, e311111537205.	0.0	0
656	Role of COL6A2 in malignant progression and temozolomide resistance of glioma. Cellular Signalling, 2023, 102, 110560.	1.7	1
657	Impact of EGFR289T/V mutation on relapse pattern in glioblastoma. ESMO Open, 2023, 8, 100740.	2.0	1
658	High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac - workflow and initial experience with daily adapt-to-position (ATP) MR guidance: A first report. Frontiers in Oncology, 0, 12, .	1.3	12
659	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. Biomedicines, 2022, 10, 2977.	1.4	2
660	Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. Biomedicines, 2022, 10, 3205.	1.4	2
661	Ô3Ô-Ô«Ô,ÔçÔ-Ô;Ô½Ô;ÔÔÔ; Ô·Ô©Ô«Ô,Ô-Ô,ÔÔ«ÔÔ¶, ÔÔ;Ô½Ô;Ô-Ô;Ô€ÔÔ,ÔÔÔ; Ô-Ô-Ô«Ô¶Ô«Ô-Ô;Ô-Ô;Ô¶ Ô°Ô;Ô;ÔÔÔ		
662	Features of epileptiform activity in patients with diagnosed glioblastoma: from genetic and biochemical mechanisms to clinical aspects. Opuholi Golovy I Sei, 2022, 12, 102-113.	0.1	1

#	ARTICLE	IF	CITATIONS
663	Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis. <i>Radiotherapy and Oncology</i> , 2023, 181, 109435.	0.3	9
664	Gene Therapy for High Grade Glioma: The Clinical Experience. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 145-161.	1.4	9
665	Key Clinical Principles in the Management of Glioblastoma. <i>JCO Oncology Practice</i> , 2023, 19, 180-189.	1.4	12
666	Hypoxia-Induced Autophagy Is Involved in Radioresistance via HIF1A-Associated Beclin-1 in Glioblastoma Multiforme. <i>Heliyon</i> , 2023, 9, e12820.	1.4	6
667	Patterns of failure in glioblastoma multiforme following Standard (60ÂGy) or Short course (40ÂGy) radiation and concurrent temozolomide. <i>Japanese Journal of Radiology</i> , 0, , .	1.0	1
668	Cystic Glioblastoma: A Mimicker of Infection? A Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2023, 2023, 1-8.	0.2	0
669	Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	0
670	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 51-72.	0.8	0
671	New therapeutic strategies based on molecularly targeted therapy in glioblastoma " a case report and review of the literature. <i>Current Issues in Pharmacy and Medical Sciences</i> , 2022, , .	0.1	0
672	Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
673	Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. <i>Molecules</i> , 2023, 28, 1283.	1.7	5
674	Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 49, 102663.	1.7	6
675	Impact of Covid-19 pandemic on neuro-oncology multidisciplinary tumor board in the pre-vaccine era: the Normandy experience. <i>Neurochirurgie</i> , 2023, 69, 101429.	0.6	0
676	High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With 18F-GE-180. <i>Advances in Radiation Oncology</i> , 2023, 8, 101185.	0.6	2
677	RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. <i>Cancer Letters</i> , 2023, 557, 216078.	3.2	6
678	Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide. <i>Practical Radiation Oncology</i> , 2023, 13, e239-e245.	1.1	6
679	Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma. <i>PLoS ONE</i> , 2023, 18, e0274400.	1.1	0
680	MGMT methylation: Is it time to embrace the shades of grey?. <i>Neuro-Oncology Practice</i> , 2023, 10, 111-112.	1.0	0

#	ARTICLE	IF	CITATIONS
681	A feasibility, safety, and efficacy evaluation of supervised aerobic and resistance exercise for patients with glioblastoma undertaking adjuvant chemoradiotherapy. <i>Neuro-Oncology Practice</i> , 0, , .	1.0	0
682	Communication in the context of glioblastoma treatment: A qualitative study of what matters most to patients, caregivers and health care professionals. <i>Palliative Medicine</i> , 2023, 37, 834-843.	1.3	3
683	DIA-MS Based Proteomics Combined with RNA-Seq Data to Unveil the Mitochondrial Dysfunction in Human Glioblastoma. <i>Molecules</i> , 2023, 28, 1595.	1.7	3
684	Single-Cell Analysis of Unidirectional Migration of Glioblastoma Cells Using a Fiber-Based Scaffold. <i>ACS Applied Bio Materials</i> , 2023, 6, 765-773.	2.3	0
685	Glioblastoma and Other Primary Brain Malignancies in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 574.	3.8	123
687	Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
689	Treatment Patterns and Outcomes of Patients with Grade 4 Glioma Treated with Radiation during the COVID-19 Pandemic. <i>Current Oncology</i> , 2023, 30, 3091-3101.	0.9	1
691	Glioblastoma multiforme tanÄ±lÄ± olgularÄ±mÄ±zda saÄ±yalÄ± ve prognostik faktÄ±rlerin deÄ±erlendirilmesi: retrospektif Ä±salÄ±Ä±ma. <i>UludaÄ± Ä±niversitesi TÄ±p FakÄ±ltesi Dergisi</i> , 0, , .	0.2	0
692	Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2023, 59, .	0.4	1
693	The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. <i>Pharmaceutics</i> , 2023, 15, 1134.	2.0	5
694	Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view. <i>Ukrainian Neurosurgical Journal</i> , 2023, 29, 38-47.	0.1	1
695	ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. <i>Radiotherapy and Oncology</i> , 2023, 184, 109663.	0.3	30
696	Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?. <i>Current Oncology Reports</i> , 2023, 25, 777-785.	1.8	4
697	The need of radiotherapy optimization for glioblastomas considering immune responses. <i>Japanese Journal of Radiology</i> , 2023, 41, 1062-1071.	1.0	2
703	Newly diagnosed glioblastoma: A review on clinical management. , 2023, , 101-123.		0
758	Malignant Glioma. , 2023, , 3-20.		0
759	Management of Older Patients with Brain Tumors. , 2023, , 249-266.		0
769	Glioblastoma. <i>Advances in Bioinformatics and Biomedical Engineering Book Series</i> , 2023, , 261-279.	0.2	0

#	ARTICLE	IF	CITATIONS
784	Gliome. , 2024, , 23-28.		0
794	Malignome des centralen Nervensystems (ZNS). , 2024, , 1071-1107.		0
796	Brain Gliomas of Adulthood. , 2023, , 1-20.		0